Page last updated: 2024-12-11

rifamycin s

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

rifamycin S: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID122235857
SCHEMBL ID22389516
MeSH IDM0102010

Synonyms (9)

Synonym
13553-79-2
rifamycin s
SCHEMBL22389516
EN300-6505149
PD120315
(7s,11s,12r,13s,14r,15r,16r,17s,18s,19z,21z)-2,15,17-trihydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23,27,29-tetraoxo-8,30-dioxa-24-azatetracyclo[23.3.1.1^{4,7}.0^{5,28}]triaconta-1,3,5(28),9,19,21,25-heptaen-13-yl acetate
EN300-6505147
AKOS040759372
Z2587748162
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (23.33)18.7374
1990's7 (23.33)18.2507
2000's9 (30.00)29.6817
2010's6 (20.00)24.3611
2020's1 (3.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.13%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (96.88%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]